Cost-Effectiveness of Low-Molecular-Weight Heparins for Deep Venous Thrombosis
Authors: Michael K. Gould, Alan M. Garber
Journal: Annals of Internal Medicine (2000)

Letters21 March 2000Cost-Effectiveness of Low-Molecular-Weight Heparins for Deep Venous ThrombosisMichael K. Gould, MD, MSc and Alan M. Garber, MD, PhDMichael K. Gould, MD, MScVeterans Affairs Palo Alto Health Care System; Stanford University School of Medicine; Stanford, CA 94305 (Gould)Veterans Affairs Palo Alto Health Care System; Stanford University School of Medicine; Stanford, CA 94305 (Garber)Search for more papers by this author and Alan M. Garber, MD, PhDVeterans Affairs Palo Alto Health Care System; Stanford University School of Medicine; Stanford, CA 94305 (Gould)Veterans Affairs Palo Alto Health Care System; Stanford University School of Medicine; Stanford, CA 94305 (Garber)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-6-200003210-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Reilly and Evans correctly note that the mortality reduction for LMWHs was a critical variable in our cost-effectiveness analysis. That is why we used meta-analysis to derive estimates of treatment effectiveness based on the best available evidence. The weight of evidence from clinical trials does not support their conclusion that LMWHs and unfractionated heparin have the same effects on mortality rates in the treatment of deep venous thrombosis.Deleting studies one at a time is a standard procedure used in meta-analysis to determine whether one or more studies exerted a disproportionate influence on the treatment effect. Deletion of ...Reference1. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al . Subcutaneous low-molecular-weight heparin compared with continuous unfractionated heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-82. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Michael K. Gould, MD, MSc; Alan M. Garber, MD, PhDAffiliations: Veterans Affairs Palo Alto Health Care System; Stanford University School of Medicine; Stanford, CA 94305 (Gould)Veterans Affairs Palo Alto Health Care System; Stanford University School of Medicine; Stanford, CA 94305 (Garber) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoLow-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Michael K. Gould , Anne D. Dembitzer , Gillian D. Sanders , and Alan M. Garber Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis Michael K. Gould , Anne D. Dembitzer , Ramona L. Doyle , Trevor J. Hastie , and Alan M. Garber Cost-Effectiveness of Low-Molecular-Weight Heparins for Deep Venous Thrombosis Brendan M. Reilly and Arthur Evans Metrics 21 March 2000Volume 132, Issue 6Page: 508-509KeywordsClinical trialsDeath ratesDecision makingDeep vein thrombosisForecastingHeparinInpatientsLow molecular weight heparinMortality ePublished: 15 August 2000 Issue Published: 21 March 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...